Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2017 Feb;144(2):396-404.
doi: 10.1016/j.ygyno.2016.11.019. Epub 2016 Dec 2.

Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)

Melissa Matz  1 , Michel P Coleman  2 , Helena Carreira  2 , Diego Salmerón  3 , Maria Dolores Chirlaque  3 , Claudia Allemani  2 ; CONCORD Working Group
Collaborators, Affiliations
Comparative Study

Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)

Melissa Matz et al. Gynecol Oncol. 2017 Feb.

Erratum in

Abstract

Objective: Ovarian cancer comprises several histological groups with widely differing levels of survival. We aimed to explore international variation in survival for each group to help interpret international differences in survival from all ovarian cancers combined. We also examined differences in stage-specific survival.

Methods: The CONCORD programme is the largest population-based study of global trends in cancer survival, including data from 60 countries for 695,932 women (aged 15-99years) diagnosed with ovarian cancer during 1995-2009. We defined six histological groups: type I epithelial, type II epithelial, germ cell, sex cord-stromal, other specific non-epithelial and non-specific morphology, and estimated age-standardised 5-year net survival for each country by histological group. We also analysed data from 67 cancer registries for 233,659 women diagnosed from 2001 to 2009, for whom information on stage at diagnosis was available. We estimated age-standardised 5-year net survival by stage at diagnosis (localised or advanced).

Results: Survival from type I epithelial ovarian tumours for women diagnosed during 2005-09 ranged from 40 to 70%. Survival from type II epithelial tumours was much lower (20-45%). Survival from germ cell tumours was higher than that of type II epithelial tumours, but also varied widely between countries. Survival for sex-cord stromal tumours was higher than for the five other groups. Survival from localised tumours was much higher than for advanced disease (80% vs. 30%).

Conclusions: There is wide variation in survival between histological groups, and stage at diagnosis remains an important factor in ovarian cancer survival. International comparisons of ovarian cancer survival should incorporate histology.

Keywords: epidemiology; histology; morphology; ovarian cancer; stage; survival.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

The authors declare there are no conflicts of interest.

Figures

Figure 1
Figure 1
5-year age-standardised net survival for Type 1 and Type 2 epithelial ovarian tumours by country, 2005-2009 *Data with 100% coverage of the national population. ˠ Estimate not age-standardised. ˢ Data for two or more calendar periods of diagnosis have been merged. 95% CI represented by error bars. Ranked from highest to lowest net survival by continent for women diagnosed in the calendar period of 2005-2009.
Figure 2
Figure 2
5-year age-standardised net survival for germ cell, sex cord-stromal and other specific non-epithelial ovarian tumours by country, 2005-2009 *Data with 100% coverage of the national population. ˠ Estimate not age-standardised. ˢ Data for two or more calendar periods of diagnosis have been merged. 95% CI represented by error bars. Ranked from highest to lowest net survival by continent for women diagnosed in the calendar period of 2005-2009.
Figure 3
Figure 3
5-year age-standardised net survival for localised-stage and advanced-stage ovarian tumours by country, 2004-2009 ˠ Estimate not age-standardised. ˢ Data for 2001-2003 and 2004-2009 have been merged. 95% CI represented by error bars.
See this image and copyright information in PMC

References

    1. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2) Lancet. 2015;385(9972):977–1010. - PMC - PubMed
    1. Maringe C, Walters S, Butler J, Coleman MP, Hacker N, Hanna L, et al. Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership. Gynecologic Oncology. 2012;127(1):75–82. - PubMed
    1. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study. Lancet Oncol. 2014;15(1):23–34. - PubMed
    1. Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34(3):433–43. - PMC - PubMed
    1. Kurman RJ, Shih Ie M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol. 2011;42(7):918–31. - PMC - PubMed

Publication types